MX2022011287A - Peptidos ciclicos y sus conjugados para el direccionamiento de la integrina alfa-v-beta-6 in vivo. - Google Patents

Peptidos ciclicos y sus conjugados para el direccionamiento de la integrina alfa-v-beta-6 in vivo.

Info

Publication number
MX2022011287A
MX2022011287A MX2022011287A MX2022011287A MX2022011287A MX 2022011287 A MX2022011287 A MX 2022011287A MX 2022011287 A MX2022011287 A MX 2022011287A MX 2022011287 A MX2022011287 A MX 2022011287A MX 2022011287 A MX2022011287 A MX 2022011287A
Authority
MX
Mexico
Prior art keywords
conjugates
integrin
vivo
addressing
beta
Prior art date
Application number
MX2022011287A
Other languages
English (en)
Spanish (es)
Inventor
Johannes Notni
Neil Quigley
Katja Steiger
Original Assignee
Univ Muenchen Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Muenchen Tech filed Critical Univ Muenchen Tech
Publication of MX2022011287A publication Critical patent/MX2022011287A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
MX2022011287A 2020-03-12 2021-03-12 Peptidos ciclicos y sus conjugados para el direccionamiento de la integrina alfa-v-beta-6 in vivo. MX2022011287A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20162699 2020-03-12
PCT/EP2021/056424 WO2021180969A1 (en) 2020-03-12 2021-03-12 Cyclic peptides and their conjugates for addressing alpha-v-beta-6 integrin in vivo

Publications (1)

Publication Number Publication Date
MX2022011287A true MX2022011287A (es) 2022-12-08

Family

ID=69810651

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011287A MX2022011287A (es) 2020-03-12 2021-03-12 Peptidos ciclicos y sus conjugados para el direccionamiento de la integrina alfa-v-beta-6 in vivo.

Country Status (11)

Country Link
US (1) US20230173113A1 (cg-RX-API-DMAC7.html)
EP (1) EP4117736A1 (cg-RX-API-DMAC7.html)
JP (1) JP7787083B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220152322A (cg-RX-API-DMAC7.html)
CN (1) CN115297893B (cg-RX-API-DMAC7.html)
AU (1) AU2021233176A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022016986A2 (cg-RX-API-DMAC7.html)
CA (1) CA3175061A1 (cg-RX-API-DMAC7.html)
IL (1) IL296081A (cg-RX-API-DMAC7.html)
MX (1) MX2022011287A (cg-RX-API-DMAC7.html)
WO (1) WO2021180969A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021226432A2 (en) * 2020-05-08 2021-11-11 The Regents Of The University Of California Methods of detecting and treating lung damage in respiratory-related viral infections
CN120829485A (zh) * 2024-04-16 2025-10-24 中山医诺维申新药研发有限公司 双重靶向成纤维细胞激活蛋白和整合素亚型的化合物及其制备和应用
WO2026027771A1 (en) 2024-08-02 2026-02-05 Trimt Gmbh Alpha v beta 6-integrin binding cyclopeptides with non-natural amino acids, and conjugates thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19933173A1 (de) * 1999-07-15 2001-01-18 Merck Patent Gmbh Cyclische Peptidderivate als Inhibitoren des Integrins alpha¶v¶beta¶6¶
WO2009117531A1 (en) 2008-03-18 2009-09-24 Seattle Genetics, Inc. Auristatin drug linker conjugates
EP3107557B1 (en) 2014-02-17 2021-06-09 Seagen Inc. Hydrophilic antibody-drug conjugates
ES2898844T3 (es) * 2015-09-18 2022-03-09 Univ Muenchen Tech Ligandos para integrina alphavbeta6, síntesis y usos de los mismos
CN109563135B (zh) * 2016-06-13 2024-01-23 加利福尼亚大学董事会 α(V)β(6)整合素结合肽及其使用方法
WO2019154842A1 (en) * 2018-02-06 2019-08-15 Klinikum Rechts Der Isar Der Technischen Universität München Compound for intraoperative molecular bioimaging, method of making the same, use thereof in intraoperative molecular bioimaging and surgical method comprising intraoperative molecular bioimaging

Also Published As

Publication number Publication date
KR20220152322A (ko) 2022-11-15
CN115297893A (zh) 2022-11-04
US20230173113A1 (en) 2023-06-08
WO2021180969A1 (en) 2021-09-16
AU2021233176A1 (en) 2022-09-08
IL296081A (en) 2022-11-01
JP7787083B2 (ja) 2025-12-16
EP4117736A1 (en) 2023-01-18
CN115297893B (zh) 2025-09-23
BR112022016986A2 (pt) 2022-10-25
CA3175061A1 (en) 2021-09-16
JP2023518161A (ja) 2023-04-28

Similar Documents

Publication Publication Date Title
ECSP10010729A (es) Péptidos dirigidos a crkl
MX2024014691A (es) Enlazadores de conjugacion mejorados
CY1122155T1 (el) Συζευγμενες ενωσεις που περιλαμβανουν αντισωματα τροποποιημενης κυστεϊνης
CO6390070A2 (es) Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas incluyendo receptor de factor de crecimiento tipo insulina -i
PE20251185A1 (es) Proteinas de union condicionalmente activadas restringidas
UY32971A (es) Proteínas de unión al antígeno de la il-23 humana
ECSP099547A (es) Anticuerpos neutralizantes del citomegalovirus humano y su uso
DE60115452D1 (de) Nk zellen-aktivierende rezeptoren und deren therapeutische und diagnostische verwendungen
MX2019008538A (es) Conjugados de superficie celular y composiciones y métodos celulares relacionados.
PE20121643A1 (es) Polipeptidos del factor ix modificados y usos de los mismos
GT200600324A (es) Nuevos anticuerpos anti-igf-ir y usos de los mismos
UY33222A (es) Secuencias de aminoácidos dirigidas contra el receptor de superficie celular 2 de TRAIL, compuestos, construcciones y variantes efectivas
SG10201909675QA (en) Peptide vaccines for cancers expressing tumor-associated antigens
CL2011003333A1 (es) El compuesto n-{1s-[2r-(6,6'-difluoro-3'-{4s-hidroxi-1-[2s-(2s-metilamino-propionilamino)-butiril]-pirrolidin-2r-ilmetil}-1h,1'h-[2,2']biindolil-3-ilmetil)-4s-hidroxi-pirrolidin-1-carbonil]-propil}-2s-metilamino-propionamida; composicion farmaceutica; procedimiento de preparacion; compuestos intermediarios; utiles en el tratamiento de un trastorno proliferativo, tal como cancer, entre otros.
PE20190515A1 (es) Peptidos modificados de auristatina y conjugados anticuerpo-farmaco de los mismos
AR073538A1 (es) Anticuerpos multiespecificos que se unen especificamente al receptor del factor de crecimiento epidermico humano 2 (her2) y al factor de crecimiento endotelial vascular (vegf)
PE20110435A1 (es) Composiciones antagonistas del pd-1
CY1117476T1 (el) Ανταγωνιστες συμπληρωματων και οι χρησεις αυτων
MX382693B (es) Polipéptidos híbridos y quiméricos del factor viii-fc, y métodos de uso de los mismos.
UY30324A1 (es) Proteinas de fusion del rage, formulaciones y métodos de uso
CL2013003634A1 (es) Complejo que comprende una proteina de fusion que comprende, un peptido viral, peptido conector, microglobulina beta 2 , peptido conector, dominios extracelulares alfa 1, 2 y 3 de mhc de clase i y un tercer peptido conector; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso
CL2008001745A1 (es) Compuestos derivados de imidazo[1,2-a]pirazina; composición farmacéutica; y uso de los compuestos como inhibidores de la proteína quinasa en el tratamiento del cáncer.
PE20040554A1 (es) Vacunas que comprenden proteinas de fusion
AR050215A1 (es) Metodo para diagnosticar enfermedades utilizando copeptina.
CO2024012877A2 (es) Conjugados de fármaco-anticuerpo dirigidos al receptor de folato alfa y métodos de uso